Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Strokes and net clinical benefit

H White1

  • 1Green Lane Hospital, Auckland, New Zealand.

Australian and New Zealand Journal of Medicine
|December 1, 1993
PubMed
Summary

The GUSTO trial assessed stroke incidence with thrombolytic drugs. Accelerated tissue plasminogen activator (t-PA) showed better net clinical benefit than streptokinase (SK) regimens, despite varying stroke rates.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The gut microbiota in adults with cystic fibrosis compared to colorectal cancer.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society·2023
Same author

Estimation of genetic parameters for feed efficiency traits using random regression models in dairy cattle.

Journal of dairy science·2023
Same author

Body mass index and nutritional intake following Elexacaftor/Tezacaftor/Ivacaftor modulator therapy in adults with cystic fibrosis.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society·2023
Same author

Can ultrasound strain elastography (USE) improve management of suspicious thyroid nodules measuring <10 mm? A systematic review.

Radiography (London, England : 1995)·2023
Same author

Diabetes is associated with increased burden of gastrointestinal symptoms in adults with cystic fibrosis.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society·2023
Same author

Cystic Fibrosis-Related Gut Dysbiosis: A Systematic Review.

Digestive diseases and sciences·2023

Area of Science:

  • Cardiology
  • Neurology
  • Clinical Trials

Background:

  • Assessing stroke incidence is crucial when comparing effective thrombolytic therapies.
  • The GUSTO trial design incorporated careful stroke incidence evaluation.

Purpose of the Study:

  • To analyze stroke incidence across different thrombolytic regimens in the GUSTO trial.
  • To evaluate the net clinical benefit by balancing stroke risk and mortality reduction.

Main Methods:

  • Comparison of stroke incidence rates between various treatment groups.
  • Calculation of net clinical benefit considering both adverse events (stroke) and positive outcomes (mortality reduction).

Main Results:

  • Stroke incidence varied: 1.22% (streptokinase/subcutaneous heparin), 1.4% (streptokinase/intravenous heparin), 1.55% (t-PA/intravenous heparin), and 1.64% (combination t-PA/streptokinase).
  • Net clinical benefit analysis favored the accelerated tissue plasminogen activator (t-PA) regimen over streptokinase (SK) regimens.

Conclusions:

  • The GUSTO trial demonstrated differential stroke incidence based on thrombolytic drug and heparin administration.
  • Accelerated t-PA therapy offered superior net clinical benefit compared to SK-based treatments in this trial.

Related Experiment Videos